Biotech Values

[DewDiligence]

BLUE—Ayrmid Ltd is a small private-equity firm incorporated in 2024 that has been involved in several deals with distressed biotech companies. Ayrmid’s main asset is 100% ownership of Israel’s Gamida Cell (https://www.gamida-cell.com/contact/ ), which was publicly traded until Ayrmid acquired it in Jun 2024.

BLUE is trading at $4.55 in the AH session ($0.05 above Ayrmid’s offer excluding the CVR), suggesting that investors expect a modest bidding war to ensue.